Begin typing your search above and press return to search.
exit_to_app
When UAPA is invoked against fact-finding efforts
access_time 2021-11-17T18:18:11+05:30
Aylan Kurdis dying again
access_time 2021-11-27T09:15:10+05:30
Viral job seeker, finally appointed
access_time 2021-11-26T15:57:19+05:30
Oil market price war resurfacing
access_time 2021-11-27T09:18:19+05:30
Child smugglers should be punished
access_time 2021-11-25T12:56:54+05:30
If the fire of hatred is not extinguished
access_time 2021-11-24T09:00:53+05:30
exit_to_app
Homechevron_rightIndiachevron_rightCovaxin efficacy meets ...

Covaxin efficacy meets WHO standards, safe to use, says Joint Drugs Controller

text_fields
bookmark_border
Covaxin efficacy meets WHO standards, safe to use, says Joint Drugs Controller
cancel

New Delhi: Covaxin, the Covid the vaccine developed by Bharat Biotech, has satisfactory efficacy levels prescribe by World Health Organisation (WHO) and there is nothing to worry said S. Eswara Reddy, Joint Drugs Controller, Central Drugs Standard Control Organisation (CDSCO), said on Saturday that

Allaying the apprehensions associated with the safety of the vaccine, Speaking at the JITO Professional Forum (JPF) through video conferencing, Reddy said that according to the World Health Organization (WHO), the minimum efficacy of any vaccine should be at least 50 per cent, which is considered as the passing mark for any vaccine.

Indicating at Covaxin's efficacy meeting the WHO standard, Reddy said, "We assure that the vaccine is safe and the efficacy (of Covaxin) is to the satisfaction."

Reddy spoke on the subject 'Making Sure Vaccine is Safe'.

He added that the government will closely monitor all those receiving the Covid vaccine dose. "A robust programme has been built to monitor all the beneficiaries," Reddy said.

He emphasised that vaccination is extremely important to break the chain of transmission of novel coronavirus.

Reddy also spoke on the aspect of immunity of these vaccines. "It is clearly not known as to how long the immunity will last (for these vaccines)," he said.

However, Reddy added that usually it is expected that the vaccines will give lifelong immunity.

Citing the data involved in Covaxin approval, he said that the Phase 3 trials involved 24,000 subjects; and for Covishield, manufactured by the Serum Institute of India, the government has UK's Phase 3 efficacy data.

Reddy said that India has the infrastructure to develop 2 billion vaccine doses per annum, and it can very well meet its domestic demand, and also import vaccines to other countries.

He also elaborated on the methodology deployed to calculate the efficacy of the vaccines, and stressed that all procedures were followed leading to the vaccination drive.

Another speaker at the webinar, G.C. Khilnani, Chairman, pulmonary and critical care and sleep medicine, at the PSRI Hospital in Delhi, said that normally it takes 8 to 10 years to develop a vaccine. The Indian Covid vaccine's Phase 2 and 3 trials were combined, due to which the vaccine could be preapared in nine months.

Moments after Prime Minister Narendra Modi launched the vaccination drive across the country virtually on Saturday morning, the jab was administered to a sanitation worker at the AIIMS in New Delhi. The government is targeting to vaccinate close to 30 crore people in the next five to six months.

(From IANS with edits)

Show Full Article
TAGS:Covid Updates Covaxin WHO 
Next Story